New Directors Bring Extensive Leadership Experience in Corporate Strategy and CommercializationSEATTLE and VANCOUVER, British ...

Slaoui, Ph.D., has served as the Chief Corporate Development Officer at Galderma, a leading global dermatology company, since 2020 ... Prior to joining Galderma, Dr. Slaoui spent 20 years at GSK, ...

SEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company ... 20 years at GSK, contributing to ...

ACHV READ THE FULL ACHV RESEARCH REPORT Update for 2025 Achieve Life Sciences, Inc. (NASDAQ:ACHV) has been busy since its ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specializes in the treatment of rare ...

Luke Miels, GSK’s chief commercial officer, stated that the acquisition is consistent with the company’s strategy of acquiring assets targeting validated medical needs, even in areas where ...

British drug maker GSK on Monday said it will buy US biopharmaceutical company IDRx for up to $1.15 billion. The Boston-based biotechnology firm is developing therapeutics for the treatment of ...

GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.

The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...